Replies to post #99547 on Biotech Values

[DewDiligence]

That was definitely the case with Lovenox and I think it's the case with Copaxone, but it's academic, IMO. I don't expect NVS/MNTA to launch Copaxone "at-risk" unless the patent case goes unambiguously their way in the lower court.